(Q38168304)

30 August 2017

title

The discovery and development of vandetanib for the treatment of thyroid cancer (English)

1 reference

30 August 2017

Michael W Sim

1

1 reference

30 August 2017

Mark Steven Cohen

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

4 December 2013

1 reference

Expert Opinion on Drug Discovery

30 August 2017

published in

1 reference

30 August 2017

volume

9

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

105-114

1 reference

Medullary thyroid carcinoma: management of lymph node metastases

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib and the management of advanced medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Gastrointestinal manifestations of multiple endocrine neoplasia type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Medullary thyroid cancer: management guidelines of the American Thyroid Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Medullary Thyroid Carcinoma: Long-Term Outcomes of Surgical Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Treatment of medullary thyroid carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib: in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Update in thyroidology 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Cardiovascular safety profile of dapoxetine during the premarketing evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.866942

10.1517/17460441.2014.866942

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference